Form 4: Immunome CEO Clay B. Siegall Acquires 800,000 Stock Options
SEC Form 4 Filing
Immunome Inc. CEO Clay B. Siegall reports the acquisition of 800,000 stock options in a Form 4 filing with the SEC.
Summary
- Clay B. Siegall, the President and CEO of Immunome Inc., filed a Form 4 with the SEC on August 13, 2024.
- The filing reports a transaction that occurred on August 9, 2024, where Siegall acquired 800,000 stock options.
- The exercise price of these options is $12.92.
- The options vest over time, with 25% vesting on August 9, 2025, and the remaining shares vesting monthly thereafter over 36 months.
- The options expire on August 8, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. This is a standard SEC filing related to stock option grants. The CEO's acquisition of options could be interpreted as a positive signal, but it's a routine part of executive compensation.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates changes in the CEO's beneficial ownership of Immunome Inc. securities.
Stakeholder Impact
- Shareholders may view the CEO's stock option acquisition as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of transaction: CEO acquired 800,000 stock options. |
| 08/09/2025 | 25% of the acquired stock options vest. |
| 08/08/2034 | Expiration date of the stock options. |
| 08/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.